Id and Rd Maintenance Regimens After Induction of Remission in Multiple Myeloma.

Newly Diagnosed Myeloma Patients, who achieved efficacy above VGPR (very good PR)after initial treatment were enrolled. Patients were then randomly assigned to Id and Rd groups for maintenance treatment. Therapeutic effectiveness will be reviewed monthly until intolerant side effect or disease progression appear . The follow-up period is approximately 2 years.

Trial Details

NCT ID
NCT05477797
Phase
NA
Sponsor
RenJi Hospital
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • Ixazomib DX/Lenalidomide DX
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Adult male or female patients aged 18 years or older with a confirmed diagnosis of symptomatic diagnosed multiple myeloma. Patients who have previo…
  • An informed consent form (ICF) has been signed. Considering the patient's condition, if the patient's signature is not conducive to the treatment o…
  • Female patients of child-bearing potential should meet both of the following criteria:
  • Take effective contraceptive measures during the study and for three months following the last dose;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →